CHARLOTTETOWN – A U.S. tobacco leaf merchant has acquired majority stakes in a PEI licensed medical marijuana producer and a cannabis company that is developing indoor growing operations in Ontario.

With the legalization of cannabis just around the corner, 89 licensed producers (and counting) will need to find ways to make their businesses competitive in what is predicted to be one of the most lucrative industries of 2018.
OTTAWA ­– A doctor’s group representing most of the country’s physicians wants cannabis labeling controlled by federal government.
GATINEAU – The Hydropothecary Corporation today released Elixir CBD Peppermint, Canada's first CBD medical cannabis oil mist.
TORONTO – Licensed marijuana producer Aphria Inc. has signed a deal to sell its stake in Arizona cannabis company Copperstate Farms to an affiliated U.S. company, Liberty Health Sciences Inc., for $20 million.
Sunrise Genetics is the first organization to provide a complete assembly of the cannabis genome. They presented their work at the 26th Plant and Genome Conference, which ran from Jan. 13 -17 of 2018.

I gave the President and COO of Sunrise Genetics, Matt Gibbs a call in Colorado to talk about the advent of cannabis genomics research and what it means for licensed cannabis producers in 2018 and beyond.

This is our interview:

: Let’s start by talking about what it is that Sunrise Genetics does.

Matt: Sunrise genetics is a biotechnology company that specializes in cannabis genomics.

We develop different genomics tools to advance the breeding effort of cannabis and to better understand the plant.

Through understanding of the genes in the cannabis genome, we’re able to build different tools to understand how the plant works or produces a certain chemical or fights off pests, or how drought-tolerant it is.

J: How does investing in genetic research benefit licensed cannabis producers?

M: Consumers want a consistent product whether it is recreational or medicinal. The LPs want to make sure they can deliver what it is the consumer wants.

These tools can identify a plant genetically so that there is transparency from the very beginning. And give their customers assurance. We can provide that.

It’s also important for LPs to differentiate themselves. To create novel and consistent plants and monetize their new creation. There are a variety of ways we provide value to LPs.

J: The most commonly known cannabinoids are THC and cannabidiol. With your mapping of the cannabis genome, what other cannabinoids have you found in the plant so far, and what would their applications be?

M: Actually, there are many genomic maps of cannabis. But what we’ve done is we’ve created the first one that is actually ordered into the 10 chromosomes of the plant.

Think about it like a map that’s now been ordered into the shape of Canada – it’s been put into all the provinces, and broken down further into the cities. And we also know the topography of the map.

And so this means we can put flags in different places that identify where to find THC or cannabidiol, or anything else, in the genome.

J: And before the genetic map, scientists and researchers would run into problems like…?

M: Well, there was no agreed upon standards from which to replicate anyone else’s work, so from a scientific perspective, there were claims that could not be reproduced or proven.

With a map, we can all agree on boundary lines, where things are, and the distance between them and it allows us to accelerate breeding, it allows us to accelerate the discovery of genes, and eventually it will allow for legitimate clinical trials.

We’re just starting to understand the plant at its DNA level because now we can agree upon a map from which to experiment from.

J: So really it’s similar to the 23 & Me product in that I can give their lab a strand of my hair or some skin cells and they would analyze it and send me a package in the mail detailing my likelihood for male pattern-baldness, autism, or high-blood pressure?

M: That’s what it will move towards. Think of 23 & Me but go back to painted chromosomes. It won’t be able to tell you you’re going to bald yet, but it can in a year or two.

What I would say is the assembly of the genome itself will be the basis from which we can launch a whole bunch of new ways to identify and categorize the plant that may be useful to you as a consumer.

We’re just at the beginning but that is what we will get to, and a lot of it will depend on what the LPs want.

J: At what level should an LPs use this kind of research on the traits in their plants? Small? Mid-level? International?

M: These tools can be used at every level. From simple things like sex testing, or producing markers, to help understand the stability of cannabinoids and terpenes and other traits related to the plant’s growth.

It’s about understanding what your plant catalogue is and identifying what you’d like to breed for improvement.

J: Do you see any push-back or skepticism about cannabis genomics?

M:Plenty. It’s science that’s been applied to many other crops and organisms in the world but it’s new to cannabis, and cannabis is new to legalization, so it’s part of us all growing as an industry and understanding what’s available to us, not being afraid of the unknown.

So the skepticism is understood, and it would be weird if there wasn’t any.

J: What’s an example of something that producers would want to see accelerated in their plant?

M:  Any of the cannabinoids really. THC and CBD – they (the clients) want to know how to regulate and stabilize those two in a variety of ratios.

The goal could also be to produce seeds that are much more disease free, that have greater vigour, are cheaper to manage, or identifying the seeds that are capable of high THC production.

We can save them time and resources they would otherwise spend on “pheno hunting”. (Breeding for a specific phenotype expression in a plant, like high bud yield)

J: Do you see the work you’re doing now as an industry standard in the future? And why?

M: It likely will be a standard in the industry. It has broad implications for plant improvement and discovery of plants abilities so I think genomics is going to be the scientific basis from which the LP can choose what to commercialize and leverage for their benefit.

For more information about Sunrise Genetics, click here. 

On January 25, Health Canada announced two changes to the physical security requirements under the Access to Cannabis for Medical Purposes Regulations (ACMPR), which impact licensed producers (LPs) of cannabis for medical purposes. 
TORONTO – Licensed marijuana producer Aphria Inc. announced an agreement Monday to buy medical cannabis firm Nuuvera Inc. in a cash-and-stock deal that it says values the company at $826 million.
LIVERPOOL, NOVA SCOTIA — Aqualitas Inc.  has been granted a licence to cultivate medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR).

EDMONTON – Aurora Cannabis Inc. has struck a friendly deal valued at $1.1 billion to buy rival licensed producer CanniMed Therapeutics Inc., bringing an end to a hostile takeover battle between the marijuana companies.
TORONTO – While Ontario landlords are looking to ban marijuana use in their rental units and several municipalities don't want legal cannabis stores in their neighbourhoods, a U.S. study suggests that pot could lift property values.
FREDERICTON – New Brunswick has signed a deal with a fourth company to supply marijuana for the province's recreational market.
2018 began with a bang in the Canadian cannabis industry.  After the markets closed this past Friday, January 12, 2018, CanniMed Therapeutics Inc. (“CanniMed”), announced that it had commenced a lawsuit against Aurora Cannabis Inc. (“Aurora”) and a number of large CanniMed shareholders.

In the announcement, CanniMed indicated that the claim was for $725 million in damages resulting from the defendants’ (alleged) “unlawful actions that have negatively affected the appreciation of the value of common shares of CanniMed and prevented CanniMed from pursuing alternative change of control transactions for the benefit of the CanniMed shareholders.”

TORONTO – Cannabis Compliance Inc. of Toronto will make a strategic investment in 3|Sixty Transport Ltd. to acquire a 40% stake in the company that provides complete beginning to end security solutions for Canadian medical cannabis producers, according to a press release.

TORONTO –Newstrike Resources Ltd. welcomes a statement from Canada's iconic musicians, The Tragically Hip, in strong support of Up Cannabis continuing to reach important milestones and Newstrike's agreement to combine with CanniMed Therapeutics Inc.

Subscription Centre

New Subscription
Already a Subscriber
Customer Service
View Digital Magazine Renew

Most Popular

We are using cookies to give you the best experience on our website. By continuing to use the site, you agree to the use of cookies. To find out more, read our Privacy Policy.